American Association for Cancer Research
Browse
23266066cir180309-sup-201606_1_supp_4926813_pcppr8.pptx (38.89 kB)

Figure S4 from Antibody-Neutralized Reovirus Is Effective in Oncolytic Virotherapy

Download (38.89 kB)
figure
posted on 2023-04-03, 22:41 authored by Robert A. Berkeley, Lynette P. Steele, Aat A. Mulder, Diana J.M. van den Wollenberg, Timothy J. Kottke, Jill Thompson, Matthew Coffey, Rob C. Hoeben, Richard G. Vile, Alan Melcher, Elizabeth J. Ilett

Hand-off of reoNAb by monocytes is contact-dependent

Funding

University of Leeds PhD scholarship

History

ARTICLE ABSTRACT

Immunotherapy is showing promise for otherwise incurable cancers. Oncolytic viruses (OVs), developed as direct cytotoxic agents, mediate their antitumor effects via activation of the immune system. However, OVs also stimulate antiviral immune responses, including the induction of OV-neutralizing antibodies. Current dogma suggests that the presence of preexisting antiviral neutralizing antibodies in patients, or their development during viral therapy, is a barrier to systemic OV delivery, rendering repeat systemic treatments ineffective. However, we have found that human monocytes loaded with preformed reovirus–antibody complexes, in which the reovirus is fully neutralized, deliver functional replicative reovirus to tumor cells, resulting in tumor cell infection and lysis. This delivery mechanism is mediated, at least in part, by antibody receptors (in particular FcγRIII) that mediate uptake and internalization of the reovirus/antibody complexes by the monocytes. This finding has implications for oncolytic virotherapy and for the design of clinical OV treatment strategies. Cancer Immunol Res; 6(10); 1161–73. ©2018 AACR.

Usage metrics

    Cancer Immunology Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC